Patents Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services
  • Publication number: 20200095331
    Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Hisataka Kobayashi, Peter Choyke
  • Publication number: 20200095548
    Abstract: Disclosed are methods of isolating T cells and TCRs having antigenic specificity for a mutated amino acid sequence encoded by a cancer-specific mutation. Also disclosed are related methods of preparing a population of cells, populations of cells, TCRs, pharmaceutical compositions, and methods of treating or preventing cancer.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 26, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Patent number: 10596334
    Abstract: A nasal delivery device can include a nasal prong and an activation member. The nasal prong can have an opening at a top and bottom portion of the prong to allow for the passage of an aerosolized treatment agent through the nasal prong. The activation member can be positioned on the nasal delivery device at a location that is spaced apart from the subject's oral cavity when the nasal prong is received into the nostril of the subject. The activation member can detect a desired exhalation state of the subject and upon detection of the desired exhalation state, the activation member activates the delivery of the aerosolized treatment agent.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: March 24, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Creare, Incorporated
    Inventors: Mark J. Papania, James J. Barry, Mark C. Bagley, James Norris, Darin A. Knaus, Eric M. Friets
  • Patent number: 10598643
    Abstract: Disclosed is a method for detecting the presence of a type I pyrethroid in an object including the steps of (a) contacting the object with a solvent and an absorbent substrate, (b) separating the absorbent substrate from the object, (c) evaporating the solvent from the absorbent substrate, (d) treating the absorbent substrate with a solution comprising a nitrite salt in concentrated sulfuric acid, and (e) observing the absorbent substrate for a color change indicating the presence of the type I pyrethroid in the object. The invention also provides a kit for detecting the presence of the type I pyrethroid in an object.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 24, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Michael D. Green
  • Patent number: 10598655
    Abstract: Disclosed are methods of detecting the presence of Loa loa in a biological sample using one or more antigens, each having a different amino acid sequence selected from the group consisting of SEQ ID NOs: 1-20. Related compositions, specific binding partners, and test kits are also disclosed.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 24, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas B. Nutman, Sasisekhar Bennuru, Papa Makhktar Drame
  • Publication number: 20200087668
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200087667
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200087716
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Applicants: Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Publication number: 20200087670
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 15, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200087669
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Application
    Filed: November 14, 2019
    Publication date: March 19, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Publication number: 20200087359
    Abstract: The invention provides modified griffithsin polypeptides comprising the amino acid sequence of SEQ ID NO: 1, as well as corresponding nucleic acids, vectors, cells, fusion proteins, constructs, conjugates, and methods of inhibiting viral infection.
    Type: Application
    Filed: November 27, 2019
    Publication date: March 19, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Louisville Research Foundation, Inc., University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Barry R. O'Keefe, Tinoush Moulaei, Kenneth E. Palmer, Lisa C. Rohan, Joshua L. Fuqua, Lindsay F. Kramzer
  • Publication number: 20200087715
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Application
    Filed: November 21, 2019
    Publication date: March 19, 2020
    Applicants: Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10588984
    Abstract: The present disclosure is directed to methods and compositions for the diagnosis and/or treatment of tumors, such as ocular tumors, using virus-like particles conjugated to photosensitive molecules.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 17, 2020
    Assignees: Aura Biosciences, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Elisabet de los Pinos, John Todd Schiller, Rhonda C. Kines, John MacDougall
  • Patent number: 10590074
    Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 17, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Amy Hauck Newman, Oluyomi M. Okunola-Bakare, Jianjing Cao
  • Publication number: 20200080057
    Abstract: Disclosed are methods of preparing thymic emigrant cells in vitro, isolated or purified thymic emigrant cells prepared by the methods, and pharmaceutical compositions comprising the same. Further disclosed are methods of treating or preventing a condition in a mammal comprising administering the thymic emigrant cells or pharmaceutical compositions comprising the same to the mammal.
    Type: Application
    Filed: December 13, 2017
    Publication date: March 12, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Raul E. Vizcardo, Nicholas D. Klemen, Nicholas P. Restifo
  • Patent number: 10583410
    Abstract: Disclosed herein are aerosol particle growth systems including polymer electrolyte membranes and related methods of increasing the size of aerosol particles. In some embodiments, an outer housing contains a reservoir of a working fluid, and a PEM conduit extends through the outer housing, the reservoir, and the working fluid so that the working fluid is in contact with an outer surface of the PEM conduit. The conduit can be generally helical or coiled, for example. In some embodiments, the working fluid is molecularly transported across the PEM and disperses into an aerosol flowing through the PEM conduit. As the aerosol flows through the PEM conduit, the aerosol particles act as nucleation sites for the gaseous working fluid, which condenses on the particles, causing the particles to grow in size and making them easier to detect, collect, measure, count, study, or otherwise investigate.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: March 10, 2020
    Assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Regents of the University of Minnesota
    Inventors: Pramod S. Kulkarni, Jikku Moolamkunnam Thomas, Christopher J. Hogan, Jr.
  • Patent number: 10583173
    Abstract: Disclosed is a method of treating, reducing, or preventing pruritis in a mammal, the method comprising administering at least one natriuretic polypeptide b (Nppb) blocking agent to a mammal in an amount effective to treat or prevent pruritis in the mammal. An in vitro method of identifying a compound that inhibits Nppb activity is also disclosed.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mark A. Hoon, Santosh K. Mishra
  • Patent number: 10584387
    Abstract: Viral infection has been suspected in the development of primary Sjögren's syndrome (pSS). Using a custom viral microarray, hepatitis delta virus (HDV) genomes and antigens were detected in minor salivary glands of patients with pSS. Expression of HDV antigens in healthy mice led to a Sjögren's syndrome-like pathogenesis characterized by a reduction in salivary flow, increase in lymphocytic foci, and the development of an autoantibody profile similar to HDV-positive patients. Also described herein is the detection of HDV in patients diagnosed with lymphoma. Expression of HDV antigen in healthy mice resulted in the development of tertiary lymphoid structures characteristic of the early stages of lymphoma. A sensitive, nested qPCR assay to detect HDV transcript and/or HDV genome in patient samples is also described.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: March 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Melodie L. Weller, John A. Chiorini
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10584161
    Abstract: Monoclonal antibodies that specifically bind the nucleocapsid protein of Heartland virus (HRTV) are described. The monoclonal antibodies can be used, for example, in immunoassays to detect HRTV-specific antibodies in a biological sample or to detect HRTV in a cell or tissue sample. The monoclonal antibodies can also be used to diagnose or treat an HRTV infection.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: March 10, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Amanda E. Calvert, Aaron C. Brault